The monomeric yellow fluorescent protein (YFP) gene was inserted in-frame right after the initiation codon of the Bcl6 gene such that the product of this allele would be the YFP-Bcl6 fusion protein. Bcl6 protein expression can be analyzed by flow cytometry. Fluorescence of YFP-Bcl6 in most most cell types is too dim to be analyzed by microscopy unless cells/tissues are stained with anti-GFP and a fluorescent dye-labeled secondary antibody.Homozygous animals. YFP-Bcl6 is functionally compromised, possibly because fusion with YFP near the BTB domain of Bcl6 might impair recruitment of the corepressor molecules or disrupt the formation of Bcl6 homodimers or heterodimers with other BTB domain-containing transcription factors. Therefore, homozygous animals are hypomorphic. Heterozygous animals are largely normal. <a href='https://brc.riken.jp/mus/pcr10015'>Genotyping protocol -PCR-</a> Bruce 4 [B6.Cg-Thy1<a>] true 岡田峰陽、2007-2009、理化学研究所免疫・アレルギー科学総合研究センターにて作成 由来：B6N/B6J F1-hybrid ES 主に兄妹交配（F30）、B6Jへの戻し交配５回（N5） SPF環境でのホモ接合体での致死性なし、発育良好、雌雄とも繁殖に問題なし。 ホモ接合体では、抗体産生応答、とくに胚中心反応の減弱あり。 岡田峰陽、2007-2009、理化学研究所免疫・アレルギー科学総合研究センターにて作成由来：B6N/B6J F1-hybrid ES主に兄妹交配（F30）、B6Jへの戻し交配５回（N5）SPF環境でのホモ接合体での致死性なし、発育良好、雌雄とも繁殖に問題なし。ホモ接合体では、抗体産生応答、とくに胚中心反応の減弱あり。 Developed by Takaharu Okada, RIKEN Research Center for Allergy and Immunology around 2007-2009. Bruce 4 ES cells were used and mice were backcrossed to C57BL/6J for 5 generations. The monomeric yellow fluorescent protein (YFP) gene was inserted in-frame right after the initiation codon of the Bcl6 gene such that the product of this allele would be the YFP-Bcl6 fusion protein. Bcl6 protein expression can be analyzed by flow cytometry. Fluorescence of YFP-Bcl6 in most most cell types is too dim to be analyzed by microscopy unless cells/tissues are stained with anti-GFP and a fluorescent dye-labeled secondary antibody. YFP-Bcl6 is functionally compromised, possibly because fusion with YFP near the BTB domain of Bcl6 might impair recruitment of the corepressor molecules or disrupt the formation of Bcl6 homodimers or heterodimers with other BTB domain-containing transcription factors. Therefore, homozygous animals are hypomorphic. Heterozygous animals are largely normal. <A HREF="https://mus.brc.riken.jp/en/mouse_of_month/jan_2019_mm" target="_blank">Mouse of the Month Jan 2019</A> B6.Cg-Bcl6<tm1.1Toka> B6.Cg-Bcl6<tm1.1Toka> Cre/loxP system 条件を付加する。<br>研究成果の公表にあたって寄託者の指定する文献を引用する。Immunity, 34(6), 961-972 (2011).<br>営利機関の利用希望者は、事前に利用条件等につき寄託者と合意し、提供承諾を得ること。利用者が本件リソースを使用して得られた研究成果に基づき特許等の申請、及び事業活動を行う場合は、寄託者と別途協議を行う。 Necessary documents for ordering:<ol><li>Order form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_4.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_b.docx">English</A>)</li><li>Category I MTA: MTA for distribution with RIKEN BRC (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_5.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_c.docx">English</A>)</li><li>Acceptance of responsibility for living modified organism (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_7.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_g.docx">English</A>)</li><li>GFP Transfer License (<A HREF="https://web.brc.riken.jp/ja/method/link/gfp_conclude">Japanese</A> / <A HREF="https://web.brc.riken.jp/en/method/link/gfp_conclude">English</A>)<br>Please fill in the <A HREF="https://web.brc.riken.jp/en/wp-content/uploads/form/gfp_schedule_a.doc">Schedule A</A>, and submit two signed copies to us together with two signed copies of RIKEN BRC's MTA. Please also read <A HREF="https://web.brc.riken.jp/en/wp-content/uploads/form/gfp_schedule_b.doc"> Schedule B</A>. </li></ol> C (3-6 months) Fluorescent Proteins/lacZ System C（3〜6か月） In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. Immunity, 34(6), 961-972 (2011).For use of the BIOLOGICAL RESOURCE by a for-profit institution, the RECIPIENT must reach agreement on terms and conditions of use of it with DEPOSITOR and must obtain a prior written consent from the DEPOSITOR. The RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE. RBRC10015 phage P1 LoxP site, Aequorea victoria GFP variant(EYFP)cDNA, mouse Bcl6 genomic DNA YFP-Bc16 YFP-Bc16